Research & Development

Xentria receives ODD from EMA for anti-TNFα monoclonal antibody

Xentria has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for its anti-TNFα monoclonal antibody, XTMAB-16.

OrsoBio raises $60m to advance treatment for obesity and associated disorders

OrsoBio has raised $60m in Series A financing to advance its metabolic portfolio for the treatment of obesity and associated disorders.

Halozyme, Acumen partner for ENHANZE drug delivery technology

Halozyme Therapeutics and Acumen Pharmaceuticals have signed a global collaboration and non-exclusive license agreement for the ENHANZE drug delivery technology in Alzheimer's disease.

Noramco buys Drug Product Business Unit from Cambrex

US-based Noramco has acquired the Cambrex Drug Product Business Unit, which was formerly known as Halo Pharmaceuticals.

Basilea, iNtRON sign deal for antibacterial agent

Basilea Pharmaceutica and iNtRON Biotechnology have signed an exclusive evaluation license and option agreement for the potential first-in-class clinical-stage antibacterial agent, tonabacase.

Canada’s PharmaDrug signs agreement to acquire Securedose Synthetics

Canadian company PharmaDrug has signed a definitive agreement to acquire Securedose Synthetics, a privately-held pharmaceutical research and development company.

ThermoGenesis opens cell and gene therapy facility in Sacramento, US

ThermoGenesis Holdings has opened a new 35,500ft² ReadyStart-IncuStart cGMP facility in Greater Sacramento in Northern California, US.

Caris, Moderna partner for mRNA-based oncology therapeutics advancement

Caris Life Sciences and Moderna have signed a new multi-year agreement for advancing mRNA-based oncology therapeutics.

Synaffix, ABL Bio partner to develop bispecific ADCs

Lonza company Synaffix has signed a licensing agreement with ABL Bio for the development of bispecific antibody drug conjugates (ADCs).